Back to Trials
NCT05046080Recruiting

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

M.D. Anderson Cancer Center

Start Date

8/6/2021

Completion Date

9/29/2026

Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Detailed Description

PRIMARY OBJECTIVE: I. To perform a retrospective clinicopathologic study on patients diagnosed and treated for clear cell carcinoma of the cervix at M D Anderson Cancer Center (MDACC) and to delineate the immunohistochemical and molecular profile of these cases. OUTLINE: Patients' medical records are reviewed retrospectively, and archival tumor tissue analyzed by immunohistochemistry and next generation sequencing.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Patients diagnosed with clear cell carcinoma of the cervix at MDACC

Interventions

OTHER

Electronic Health Record Review

OTHER

Laboratory Biomarker Analysis

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

Locations

M D Anderson Cancer Center

Houston, Texas 77030

United States